InvestorsHub Logo
Post# of 251701
Next 10
Followers 56
Posts 1150
Boards Moderated 0
Alias Born 11/12/2005

Re: dumaflotchie post# 117340

Wednesday, 03/30/2011 8:34:57 PM

Wednesday, March 30, 2011 8:34:57 PM

Post# of 251701
That analysis has been pretty much completely discredited elsewhere. A single Phase III trial in a non-orphan indication costs $55M.

Unless otherwise indicated, this is the personal viewpoint of David
Miller and not necessarily that of Biotech Stock Research, LLC.
We're on Twitter at BiotechStockRsr

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.